With an increase in aging populations worldwide, age-related diseases such as Alzheimer’s disease (AD) have become a global concern. At present, a cure for neurodegenerative disease is lacking. There is an urgent need for a biomarker that can facilitate the diagnosis, classification, prognosis, and treatment response of AD. The recent emergence of highly sensitive mass-spectrometry platforms and high-throughput technology can be employed to discover and catalog vast datasets of small metabolites, which respond to changed status in the body. Metabolomics analysis provides hope for a better understanding of AD as well as the subsequent identification and analysis of metabolites. Here, we review the state-of-the-art emerging candidate biomarkers for AD.

No abstract

No abstract

One new C21-steroid, pregnane A (1), and two new anolides daturafolisides X and Y (2 and 3), together with six known with anolides (4–9), were isolated from the roots of Datura metel L. The structures of these compounds were established by 1D and 2D NMR spectra and mass spectroscopy by comparing our results with the literature values. Compounds 1–9 were evaluated for inhibition against nitric oxide production in lipopolysaccharide-induced RAW 264.7 macrophages. It was found that the isolated compounds showed the different levels of anti-inflammatory activities with IC50 values ranging from 24.2 to 43.4 μmol/L.

No abstract